Loading
Life sciences · Phase 1/2 Trial
ClinicalTrials.gov · October 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1/2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06590857). This is a study registration, not published results. Lead sponsor: RayzeBio, Inc.. Recruitment status: RECRUITING. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 64 participants (ESTIMATED). Conditions: Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer With Bone Involvement, Bone Metastases in Subjects With Advanced Breast Cancer, ER-Positive HER2-Negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Hormone-sensitive Metastatic Breast Cancer, Hormone-Sensitive Breast Cancer. Interventions: DRUG: RYZ101; DRUG: Standard of Care Endocrine Therapy. Primary outcome measures: Dose Escalation , 6 weeks of RYZ101 treatment; Endocrine Therapy Combination Dose Escalation , [Time Frame: 6 weeks of study treatment]; Endocrine Therapy Combination Dose Escalation , Up to approximately 5 years after the last subject has completed RYZ101 treatment; Endocrine Therapy Combination Dose Escalation and Expansion , Up to approximately 5 years after the last subject has completed RYZ101 treatment; Endocrine Therapy Combination Dose Escalation and Expansion , Up to approximately 5 years after the last subject has completed RYZ101 treatment. Brief summary: Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.